NCCN 12th Annual Congress: Hematologic Malignancies™
Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances. In addition, targeted therapies and oral treatments bring the latest benefits to patients. This congress focuses on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics.
This congress is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this program, participants should be able to:
WHO Classification of Lymphoma: A Clinician's Perspective
• Describe the rationale for the revision of the WHO classification of lymphomas.
• Summarize the changes in the 2016 WHO Classification for B-cell lymphomas and T-cell lymphomas.
Updates on the Treatment of Follicular Lymphoma
• Describe the standard of care and the rationale for the development of novel treatment options for FL.
• Discuss the evidence from clinical trials supporting the use of novel targeted therapies for the management of newly diagnosed and relapsed/refractory FL.
New Options for the Management of Hodgkin Lymphoma
• Determine standard treatment options for patients with relapsed or refractory Hodgkin lymphoma.
• Identify novel immunomodulatory agents used to manage patients with relapsed or refractory Hodgkin lymphoma.
Patient Case Studies and Panel Discussion: Lymphoma
• Identify the clinical challenges in managing patients with non-Hodgkin’s lymphoma.
• Develop an evidence-based approach for the management of patients with non-Hodgkin’s lymphoma.
Managing Lymphoma Survivors
• Describe the long-term side effects associated with curative treatments for HL and NHL.
• Identify the risk factors associated with the development of long-term complications and develop an individualized follow-up schedule for survivors of HL and NHL.
Patient Case Studies and Panel Discussion: Plasma Cell Neoplasms
• Identify the clinical challenges in managing specific types and/or special situations in patients with plasma cell neoplasms.
• Develop an evidence-based approach for the management of specific types and/or special situations in patients with plasma cell neoplasms.
Management of Newly Diagnosed Multiple Myeloma in Those Eligible for Transplant
• Summarize the role of autologous stem cell transplant in the management of patients newly diagnosed with multiple myeloma.
• Select appropriate evidence-based management strategies for patients with newly diagnosed multiple myeloma.
Treatment of Relapsed/Refractory Multiple Myeloma
• Evaluate clinical data supporting the treatment options for patients with relapsed/refractory multiple myeloma.
• Summarize key clinical considerations in selecting optimal treatment regimens for patients with relapsed/refractory multiple myeloma.
Management of Common Complications Related to Multiple Myeloma and its Treatment
• Recognize various complications related to myeloma and its treatment.
• Provide appropriate supportive care measures for managing complications from myeloma and its treatment.
Palliative and End of Life Care in Hematological Malignancies
• Describe the palliative care versus end of care needs of patients with hematologic malignancies.
• Recognize situations that require palliative care specialist consultation in patients with hematologic malignancies.
Patient Case Studies and Panel Discussion: Leukemia
• Describe the clinical challenges in the management of leukemia and myeloproliferative neoplasms.
• Develop an evidence-based approach for the management of leukemia and myeloproliferative neoplasms.
Myeloproliferative Neoplasms: Management of Polycythemia Vera and Essential Thrombocythemia
• Describe the current standard of care and the role of JAK2 inhibitors in the management of patients with PV or ET.
• Develop an individualized treatment plan for PV or ET based on the risk stratification.
How to Sequence Therapy in Chronic Lymphocytic Leukemia
• Describe the current standard of care for newly diagnosed and relapsed or refractory CLL.
• Develop an appropriate plan for sequencing of therapy in patients with relapsed/refractory CLL/SLL based on prior treatment and the presence of cytogenetic abnormalities.
New Therapeutic Agents and Considerations in the Management of Acute Lymphocytic Leukemia
• Review the clinical data and discuss ongoing trials that are evaluating immunotherapy in the setting of relapsed or refractory ALL.
• Summarize major adverse events that result from immunotherapy use in the management of relapsed or refractory ALL.
Targeted Therapy for Acute Myeloid Leukemia
• Describe the standard of care and the need for novel treatment options for refractory AML.
• Identify emerging novel agents and targeted molecular abnormalities in the management of AML.
Controversies in Acute Myeloid Leukemia: Is Monitoring Minimal Residual Disease Clinically Relevant?
• Summarize current methods used to monitor minimal residual disease in acute myeloid leukemia.
• Describe the clinical utility and caveats of the methods used to monitor minimal residual disease in AML.
A block of rooms has been reserved at the Hilton San Francisco Union Square. You may book rooms by calling 1-415-771-1400. A special rate of $269.00 per night has been established for NCCN attendees. Please book your room by Tuesday, September 5, 2017 to take advantage of this special rate.
Make sure to reference NCCN when booking your room. You must be registered for the Congress to book a hotel room.
Please note that early booking is strongly encouraged as the block may sell out before the september 5, 2017 cut-off date.
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
NCCN designates this live activity for a maximum of 9.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Medical Specialties Maintenance of Certification
Through the American Board of Medical Specialties (“ABMS”) MOC Initiative to create a wide array of Maintenance of Certification (“MOC”) Activities through the ABMS MOC Directory, NCCN 12th Annual Congress: Hematologic Malignancies™ has met the MOC requirements as a MOC Part II CME Activity (apply toward general CME requirement) by the following ABMS Member Boards:
MOC Part II CME Activity
Aggregated participant data will be shared with the commercial supporters of this activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
NCCN designates this educational activity for a maximum of 8.45 contact hours.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 9.25 hours of Category I credit for completing this activity.
|National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 9.25 contact hours (0.925 CEUs) of continuing education credit. UANs: 0836-0000-17-090-L01-P through 0836-0000-17-105-L01-P
- 9.25 AMA PRA Category 1 Credit™
- 8.45 ANCC contact hours
- 9.25 Participation